NetworkNewsBreaks – BiondVax Pharmaceuticals Ltd
Post# of 122
(Total Views: 182)
Posted On: 04/03/2023 4:40:47 PM
NetworkNewsBreaks – BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) Lead NanoAb Candidate Holds Significant Advantages to Existing Therapies
BiondVax (NASDAQ: BVXV), which focuses on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, has shown, through an ongoing in vivo preclinical proof-of-concept study, that its lead NanoAb candidate for the treatment of COVID-19 exhibits clear competitive advantages over existing monoclonal antibodies (“mAbs”) and oral therapies. “According to statistically significant results released early January, BiondVax established that its inhaled therapy virtually eliminated the SARS-CoV-2 virus and prevented illness when administered prophylactically… The second set of results, announced January 23, evidenced that when the NanoAb was administered by inhalation three hours before infection, it virtually prevented the hamsters from contracting the illness… BiondVax, which aims to replicate in human trials the efficacy demonstrated so far in its animal studies, believes there will continue to be a strong demand for COVID prophylactics and treatments. This belief is supported by Pfizer’s recent report, suggesting that revenues from COVID products are expected to grow in 2024,” a recent article reads. “Encouragingly, our lead NanoAb candidate, currently being prepared for clinical trials, has demonstrated neutralization of all relevant Omicron subvariants,” BiondVax CEO Amir Reichman is quoted as saying.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
BiondVax (NASDAQ: BVXV), which focuses on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, has shown, through an ongoing in vivo preclinical proof-of-concept study, that its lead NanoAb candidate for the treatment of COVID-19 exhibits clear competitive advantages over existing monoclonal antibodies (“mAbs”) and oral therapies. “According to statistically significant results released early January, BiondVax established that its inhaled therapy virtually eliminated the SARS-CoV-2 virus and prevented illness when administered prophylactically… The second set of results, announced January 23, evidenced that when the NanoAb was administered by inhalation three hours before infection, it virtually prevented the hamsters from contracting the illness… BiondVax, which aims to replicate in human trials the efficacy demonstrated so far in its animal studies, believes there will continue to be a strong demand for COVID prophylactics and treatments. This belief is supported by Pfizer’s recent report, suggesting that revenues from COVID products are expected to grow in 2024,” a recent article reads. “Encouragingly, our lead NanoAb candidate, currently being prepared for clinical trials, has demonstrated neutralization of all relevant Omicron subvariants,” BiondVax CEO Amir Reichman is quoted as saying.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)BiondVax Pharmaceuticals Ltd. (BVXV) Stock Research Links
Scroll down for more posts ▼